183 related articles for article (PubMed ID: 27562492)
1. Erythroleukemia shares biological features and outcome with myelodysplastic syndromes with excess blasts: a rationale for its inclusion into future classifications of myelodysplastic syndromes.
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Ardanaz MT; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
Mod Pathol; 2016 Dec; 29(12):1541-1551. PubMed ID: 27562492
[TBL] [Abstract][Full Text] [Related]
2. Acute erythroid leukemia with <20% bone marrow blasts is clinically and biologically similar to myelodysplastic syndrome with excess blasts.
Wang SA; Patel KP; Pozdnyakova O; Peng J; Zuo Z; Dal Cin P; Steensma DP; Hasserjian RP
Mod Pathol; 2016 Oct; 29(10):1221-31. PubMed ID: 27443511
[TBL] [Abstract][Full Text] [Related]
3. Erythroid-predominant myelodysplastic syndromes: enumeration of blasts from nonerythroid rather than total marrow cells provides superior risk stratification.
Wang SA; Tang G; Fadare O; Hao S; Raza A; Woda BA; Hasserjian RP
Mod Pathol; 2008 Nov; 21(11):1394-402. PubMed ID: 18839018
[TBL] [Abstract][Full Text] [Related]
4. Acute erythroid leukemia as defined in the World Health Organization classification is a rare and pathogenetically heterogeneous disease.
Kasyan A; Medeiros LJ; Zuo Z; Santos FP; Ravandi-Kashani F; Miranda R; Vadhan-Raj S; Koeppen H; Bueso-Ramos CE
Mod Pathol; 2010 Aug; 23(8):1113-26. PubMed ID: 20473273
[TBL] [Abstract][Full Text] [Related]
5. Considering Bone Marrow Blasts From Nonerythroid Cellularity Improves the Prognostic Evaluation of Myelodysplastic Syndromes.
Arenillas L; Calvo X; Luño E; Senent L; Alonso E; Ramos F; Ardanaz MT; Pedro C; Tormo M; Marco V; Montoro J; Díez-Campelo M; Brunet S; Arrizabalaga B; Xicoy B; Andreu R; Bonanad S; Jerez A; Nomdedeu B; Ferrer A; Sanz GF; Florensa L
J Clin Oncol; 2016 Sep; 34(27):3284-92. PubMed ID: 27382099
[TBL] [Abstract][Full Text] [Related]
6. Comparison of genetic and clinical aspects in patients with acute myeloid leukemia and myelodysplastic syndromes all with more than 50% of bone marrow erythropoietic cells.
Bacher U; Haferlach C; Alpermann T; Kern W; Schnittger S; Haferlach T
Haematologica; 2011 Sep; 96(9):1284-92. PubMed ID: 21606170
[TBL] [Abstract][Full Text] [Related]
7. Acute erythroid neoplastic proliferations. A biological study based on 62 patients.
Domingo-Claros A; Larriba I; Rozman M; Irriguible D; Vallespí T; Aventin A; Ayats R; Millá F; Solé F; Florensa L; Gallart M; Tuset E; Lopez C; Woessner S
Haematologica; 2002 Feb; 87(2):148-53. PubMed ID: 11836165
[TBL] [Abstract][Full Text] [Related]
8. Erythroleukemia: a need for a new definition.
Park S; Picard F; Dreyfus F
Leukemia; 2002 Aug; 16(8):1399-401. PubMed ID: 12145675
[TBL] [Abstract][Full Text] [Related]
9. Enumerating bone marrow blasts from nonerythroid cellularity improves outcome prediction in myelodysplastic syndromes and permits a better definition of the intermediate risk category of the Revised International Prognostic Scoring System (IPSS-R).
Calvo X; Arenillas L; Luño E; Senent L; Arnan M; Ramos F; Pedro C; Tormo M; Montoro J; Díez-Campelo M; Blanco ML; Arrizabalaga B; Xicoy B; Bonanad S; Jerez A; Nomdedeu M; Ferrer A; Sanz GF; Florensa L
Am J Hematol; 2017 Jul; 92(7):614-621. PubMed ID: 28370234
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathologic features and outcome of acute erythroid leukemia based on 2008 revised World Health Organization classification.
Liu CJ; Hong YC; Yang CF; Liu SH; Gau JP; Liu JH; Hsiao LT; Liu CY; Yu YB; Tzeng CH
Leuk Lymphoma; 2012 Feb; 53(2):289-94. PubMed ID: 21780998
[TBL] [Abstract][Full Text] [Related]
11. Revisiting erythroleukemia.
Arber DA
Curr Opin Hematol; 2017 Mar; 24(2):146-151. PubMed ID: 27875373
[TBL] [Abstract][Full Text] [Related]
12. Re-evaluation of acute erythroid leukemia according to the 2016 WHO classification.
Chen Y; Pourabdollah M; Atenafu EG; Tierens A; Schimmer A; Chang H
Leuk Res; 2017 Oct; 61():39-43. PubMed ID: 28886412
[TBL] [Abstract][Full Text] [Related]
13. Impact of marrow blasts percentage on high-grade myelodysplastic syndrome assessed using revised international prognostic scoring system.
Alkharabsheh O; Patnaik MM; Gangat N; Begna KH; Alkhateeb HB; Shah MV; Hogan WJ; He R; Greipp P; Nguyen PL; Litzow MR; Al-Kali A
Ann Hematol; 2020 Mar; 99(3):513-518. PubMed ID: 31974678
[TBL] [Abstract][Full Text] [Related]
14. Complex or monosomal karyotype and not blast percentage is associated with poor survival in acute myeloid leukemia and myelodysplastic syndrome patients with inv(3)(q21q26.2)/t(3;3)(q21;q26.2): a Bone Marrow Pathology Group study.
Rogers HJ; Vardiman JW; Anastasi J; Raca G; Savage NM; Cherry AM; Arber D; Moore E; Morrissette JJ; Bagg A; Liu YC; Mathew S; Orazi A; Lin P; Wang SA; Bueso-Ramos CE; Foucar K; Hasserjian RP; Tiu RV; Karafa M; Hsi ED
Haematologica; 2014 May; 99(5):821-9. PubMed ID: 24463215
[TBL] [Abstract][Full Text] [Related]
15. Erythroleukemia: a comparison between the previous FAB approach and the WHO classification.
Park S; Picard F; Azgui Z; Viguie F; Merlat A; Guesnu M; Leblond V; Dreyfus F
Leuk Res; 2002 May; 26(5):423-9. PubMed ID: 11916513
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of pronormoblasts in erythrocyte predominant myelodysplastic patients.
Mazzella FM; Smith D; Horn P; Cotelingam JD; Rector JT; Shrit MA; Pesce A; Schumacher HR
Am J Hematol; 2006 Jul; 81(7):484-91. PubMed ID: 16755568
[TBL] [Abstract][Full Text] [Related]
17. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy.
Silverman LR; Greenberg P; Raza A; Olnes MJ; Holland JF; Reddy P; Maniar M; Wilhelm F
Hematol Oncol; 2015 Jun; 33(2):57-66. PubMed ID: 24777753
[TBL] [Abstract][Full Text] [Related]
18. The prognostic significance of proerythroblasts in acute erythroleukemia.
Kowal-Vern A; Cotelingam J; Schumacher HR
Am J Clin Pathol; 1992 Jul; 98(1):34-40. PubMed ID: 1615923
[TBL] [Abstract][Full Text] [Related]
19. Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.
Senent L; Arenillas L; Luño E; Ruiz JC; Sanz G; Florensa L
Haematologica; 2013 Apr; 98(4):568-75. PubMed ID: 23065505
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis and characterization of acute erythroleukemia subsets by determining the percentages of myeloblasts and proerythroblasts in 69 cases.
Kowal-Vern A; Mazzella FM; Cotelingam JD; Shrit MA; Rector JT; Schumacher HR
Am J Hematol; 2000 Sep; 65(1):5-13. PubMed ID: 10936857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
